A BBC team was able to buy over 1,600 prescription pills by supplying fake data, raising concerns over limited oversight.
A US court has granted the FTC’s request to halt the acquisition due to concerns that it will promote anticompetitive practices.
The deal is worth up to $494m plus royalties and allows Lilly to utilise Fauna’s Convergence artificial intelligence platform.
A study shared at ASH saw lupus and sclerosis patients make marked recoveries through CAR-T therapy initally targeted at blood cancers.
The plans would allow third parties to manufacture such drugs if manufacturers make them unaffordable.
Give your business an edge with our leading industry insights.
The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.
Novo Nordisk is continuing legal action against compounding pharmacies selling off-brand Ozempic which it claims are adulterated.
Autolus Theraputics is forging ahead with its T-cell cancer therapy, obe-cel, aimed at treating persistant adult ALL.
Pfizer and BioNTech countersued Moderna following an initial August 2022 suit alleging that its patents were overly broad.
Wegovy has made headlines recently in the UK, highlighting both its seismic impact and changes in health habits.